PH-responsive lactose phthalocyanine / cytarabine nano-drug and application thereof

Through pH-responsive lactose phthalocyanine/cytarabine nanodrug, combined with acoustic dynamic therapy and chemotherapy, the diagnosis and treatment of tumors are integrated, solving the problems of limited effects of phthalocyanine in acoustic dynamic therapy and great toxic side effects. , improves treatment effect and diagnostic accuracy.

CN118903418APending Publication Date: 2024-11-08XIAMEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411321953.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing phthalocyanine has limited effect in sonic dynamics therapy, making it difficult to combine diagnosis and imaging technologies simultaneously in tumor treatment, and has great toxic and side effects on normal tissues.

Method used

Using pH-responsive lactose phthalocyanine/cytarabine nanodrug, the acoustic activity of lactose phthalocyanine and cytarabine is used to combine fluorescence and photoacoustic imaging by co-assembly of lactose phthalocyanine with cytarabine. technology to realize the diagnosis and treatment of tumors.

Benefits of technology

The selective release of drugs and enhancement of fluorescence signals in the tumor microenvironment improves the therapeutic effect and diagnostic accuracy, reduces toxic side effects on normal tissues, and realizes accurate targeting and real-time monitoring of tumor sites.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903418A_ABST
    Figure CN118903418A_ABST
Patent Text Reader

Abstract

The invention discloses a pH-responsive lactose phthalocyanine / cytarabine nano-drug and an application thereof. The pH-responsive lactose phthalocyanine / cytarabine nano-drug is a nano-drug formed by co-assembling lactose phthalocyanine and cytarabine. The nano-drug is of a spherical structure with uniform particle size, can effectively realize enrichment of the drug at a tumor site, and reduces toxic and side effects in other normal tissues. The lactose phthalocyanine contained in the co-assembled nano-drug has excellent fluorescence imaging and photoacoustic imaging performance, in-vivo fluorescence and photoacoustic bimodal imaging can be achieved, and combined application of sonodynamic therapy and chemotherapy in cancers such as liver cancer can be achieved due to the high sound-sensitive activity of the lactose phthalocyanine and the chemotherapy effect of chemotherapy drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a pH-responsive lactose phthalocyanine / cytosine arabinoside nanomedicine and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Cancer has become one of the most important public health problems in the world. The main cancer treatments include surgical resection, radiotherapy, chemotherapy, etc. However, the above treatments still have certain limitations. For example, it is impossible to use imaging technology to detect and diagnose tumors while treating them to determine the size and location of the tumor.

[0003] Integrated diagnosis and treatment is an emerging biomedical technology that can simultaneously realize the diagnosis and treatment of tumors. In recent years, with the joint efforts of domestic and foreign researchers, a series of drugs that can realize the integration of tumor diagnosis and treatment have been developed, bringing new hope to human tumor treatment. Sonodynamic therapy (SDT) is a new treatment method that can realize the integration of tumor diagnosis and treatment. It refers to the sonosensitizer producing sonosensitization reaction under ultrasound irradiation, achieving anti-tumor, anti-atherosclerosis and antibacterial effects. In the process of sonodynamic therapy, sonosensitizers play a vital role. So far, many organic small molecule sensitizers, such as hematoporphyrin, phthalocyanine, sodium porphyrin, methylene blue (MB), etc., have been found to have sonodynamic activity. These organic small molecule sonosensitizers rely on ultrasound radiation to produce reactive oxygen species (ROS) and play a sonodynamic therapeutic role.

[0004] Phthalocyanine (Pc) is widely used in the field of photodynamic therapy (PDT) due to its excellent photophysical and photochemical properties and easy modification. However, PDT is limited by the depth of tissue penetration, so there have been reports of using phthalocyanine as a sonosensitizer for sonodynamic anti-tumor therapy. However, the sonodynamic therapy effect of phthalocyanine alone is limited, and further improvements are needed to improve the sonodynamic therapy effect of phthalocyanine. Summary of the invention

[0005] The present invention provides a pH-responsive lactose phthalocyanine / cytarabine nanomedicine and application thereof, which can effectively solve the above problems.

[0006] The present invention is achieved in that:

[0007] A pH-responsive lactose phthalocyanine / cytarabine nanomedicine is a nanomedicine co-assembled from lactose phthalocyanine and cytarabine.

[0008] In some embodiments, the molar ratio of lactose phthalocyanine to cytarabine is 1:4-4:1.

[0009] In some embodiments, the modification group of the lactose phthalocyanine is one of an amino group, a vitamin, and a sugar.

[0010] In some embodiments, the pH-responsive lactose phthalocyanine / cytarabine nanomedicine has a particle size of 100-200 nm.

[0011] A method for preparing the pH-responsive lactose phthalocyanine / cytarabine nanomedicine is as follows: lactose phthalocyanine and cytarabine are slowly added dropwise into water and allowed to stand for 1.5-2.5 hours to obtain a co-assembled nanomedicine.

[0012] In some embodiments, the method for preparing lactose phthalocyanine comprises the following steps:

[0013] (1) dichlorosilane phthalocyanine, p-hydroxyphenylethylamine and NaH are reacted in anhydrous toluene at 100-120° C. for 22-26 hours under nitrogen protection, hydrochloric acid is added, and after the water layer turns blue, an appropriate amount of sodium hydroxide aqueous solution is added until solids precipitate to obtain diethylaminophenoxysilane phthalocyanine;

[0014] (2) Diethylaminophenoxysilicon phthalocyanine, lactobionic acid, 1-hydroxybenzotriazole, and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride are reacted in DMF, and then separated, purified, and eluted multiple times to collect the main blue group, which is lactobionic phthalocyanine.

[0015] An application of the above-mentioned pH-responsive lactose phthalocyanine / cytarabine nanomedicine in the preparation of an integrated cancer diagnosis and treatment drug.

[0016] An application of the pH-responsive lactose phthalocyanine / cytarabine nanomedicine in fluorescence imaging.

[0017] An application of the pH-responsive lactose phthalocyanine / cytarabine nanodrug in photoacoustic imaging.

[0018] The beneficial effects of the present invention are:

[0019] The present invention relates to a lactose phthalocyanine / cytarabine nano drug with pH responsiveness, which can easily undergo a protonation reaction in a weak acid environment. This unique property enables the nano drug to achieve precise regulation of fluorescence emission intensity and drug release rate in the weak acid microenvironment surrounding tumor cells. Specifically, when the nano drug is exposed to the low pH conditions of the tumor microenvironment, the lactose phthalocyanine molecules on its surface undergo a protonation process, thereby triggering the release of the drug and enhancing the fluorescence signal, so that the drug can act more effectively at the tumor site.

[0020] The pH-responsive lactose phthalocyanine / cytarabine nanomedicine of the present invention has significant advantages in design, and can effectively enrich the drug at the tumor site, significantly reduce the distribution of the drug in normal tissues, and thus reduce the toxic side effects of the drug on normal cells. This selective drug release mechanism greatly improves the utilization rate and therapeutic effect of the drug, while reducing the patient's discomfort and potential side effect risks.

[0021] The nanomedicine of the present invention combines the high sonosensitivity of lactose phthalocyanine with the chemotherapeutic effect of cytarabine, achieving a synergistic effect of sonodynamic therapy and chemotherapy. This combined treatment strategy can not only directly destroy tumor cells through sonodynamic effects, but also further inhibit the proliferation and spread of tumor cells through chemotherapeutic drugs, thereby achieving a more comprehensive and in-depth anti-tumor effect.

[0022] The pH-responsive lactose phthalocyanine / cytarabine nanomedicine of the present invention exhibits excellent fluorescence imaging and photoacoustic imaging performance. This nanomedicine can perform fluorescence and photoacoustic dual-modality imaging in vivo, allowing doctors to diagnose tumors and evaluate treatment effects at the same time. This dual-modality imaging technology not only improves the accuracy of tumor detection, but also provides a powerful tool for real-time monitoring of the treatment process and evaluation of treatment effects, thereby providing patients with more accurate and personalized treatment plans. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 DLS (A) and TEM images (B) as well as photoacoustic intensity performance (C), UV absorption (D), and fluorescence spectrum (E) of NanoPC according to Example 2 of the present invention.

[0025] Figure 2 This is a study on the drug release and fluorescence intensity changes of NanoPC in Example 3 of the present invention under different pH environments.

[0026] Figure 3 Schematic diagram of photoacoustic and fluorescence imaging of NanoPC in cells according to Example 4 of the present invention.

[0027] Figure 4 Schematic diagram of the cytotoxicity study of NanoPC in Example 5 of the present invention and the generation of ROS and liver cancer cell death under US irradiation.

[0028] Figure 5 This is a study on the in vivo dual-modality imaging and anti-tumor properties of NanoPC according to Example 6 of the present invention. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention. Therefore, the following detailed description of the embodiments of the present invention provided in the drawings is not intended to limit the scope of the invention claimed for protection, but merely represents the selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0030] The present invention proposes a lactose phthalocyanine / cytarabine nanodrug with pH responsive properties, which is prepared by the co-assembly process of lactose phthalocyanine and cytarabine. Lactose phthalocyanine is a phthalocyanine compound axially modified with specific groups, and its sonosensitization efficiency and targeting are significantly improved. For example, the lactose group can specifically bind to the asialoglycoprotein receptor on the surface of liver cancer cells, thereby achieving active targeting of liver cancer cells.

[0031] Cytarabine (CYT) is a widely used chemotherapy drug in clinical practice. It has significant therapeutic effects, but it is also accompanied by toxic side effects that cannot be ignored. Due to the lack of targeting function, cytarabine may cause severe cytotoxic reactions during use, such as anemia and leukopenia, as well as bone marrow suppression, which has a negative impact on hematopoietic and immune functions.

[0032] The innovation of the present invention is to form a stable co-assembly by using the special groups on the axially modified phthalocyanine and the chemotherapeutic drugs through non-covalent interactions such as hydrogen bonds, van der Waals forces, and hydrophobic interactions. This axially modified phthalocyanine / cytarabine co-assembled nanomedicine can target the tumor site using the EPR effect (enhanced permeation and retention effect). At the same time, the amino group of cytarabine is easily protonated under weakly acidic conditions. In the tumor microenvironment (pH value is usually 6.5-7.4), after the amino group is protonated, the binding strength of the axially modified phthalocyanine and cytarabine is reduced, and the affinity is weakened, thereby accelerating the release of the drug and enhancing the efficiency of tumor treatment. In addition, the inhibitory effect of cytarabine on phthalocyanine fluorescence is weakened, resulting in an increase in the fluorescence emission intensity of phthalocyanine. This drug release characteristic of the tumor microenvironment response allows the drug to be effectively released at the tumor site, improves the efficacy and treatment accuracy, and is of great significance to tumor treatment. At the same time, the tumor microenvironment response realizes the contrast enhancement of the fluorescence intensity of tumor tissue and normal tissue, which helps to achieve real-time monitoring and precise positioning of the tumor site. In summary, pH-responsive lactose phthalocyanine / cytarabine co-assembled nanomedicine can effectively realize the diagnosis and imaging of liver cancer.

[0033] With the rapid development of nanotechnology, many new nano platforms have been widely used in the fields of sonosensitizers and sonodynamic therapy. At present, organic nanomedical materials mainly include liposomes, nanomicelles, nanoassembly materials, polymer nanocarriers, etc. Nanoassembly materials have attracted much attention due to their simple preparation process, easy-to-control properties, and multifunctionality. Co-(self-)assembly refers to the process in which structural units such as molecules and their nanoparticles spontaneously form thermodynamically stable and structurally determined aggregates through non-covalent interactions. This non-covalent interaction mainly includes hydrogen bonds, van der Waals forces, coordination effects, hydrophobic interactions, etc. The present invention utilizes the groups on lactose-modified phthalocyanine and the clinically commonly used chemotherapy drug arabinoside to co-assemble through non-covalent interactions. Lactose phthalocyanine / arabinoside co-assembled nanomedicine (NanoPC) can effectively enrich in liver cancer sites, reduce toxic side effects in other normal tissues, and can achieve depolymerization in the acidic microenvironment of the tumor, releasing phthalocyanine molecules and chemotherapy drugs, and realizing the combined application of sonodynamic therapy and chemotherapy in cancers such as liver cancer. This combined application not only improves the treatment efficiency, but also enables real-time monitoring and precise positioning of tumor sites through the fluorescent properties of nanomedicines, providing new possibilities for cancer diagnosis and treatment.

[0034] In some specific embodiments, the molar ratio of lactose phthalocyanine to cytarabine can be set in the range of 1:4 to 4:1. Specifically, in these embodiments, the molar ratio can be 1:4, 1:2, 1:1, 2:1 and 4:1.

[0035] In certain specific embodiments, the lactose phthalocyanine compound mentioned can be modified by introducing specific modifying groups. These modifying groups can be any one of amino groups, vitamins or sugars. In this way, the chemical properties and biological activities of lactose phthalocyanine can be significantly improved and adjusted, so that it can show better performance in specific applications. For example, the introduction of amino groups can enhance the hydrophilicity and reactivity of lactose phthalocyanine, making it easier to combine with other molecules; vitamin modification may give lactose phthalocyanine specific biological activity, making it have a wider application potential in the biomedical field; sugar modification helps to improve the solubility and stability of lactose phthalocyanine, so that it shows better biocompatibility and durability in the in vivo environment.

[0036] In certain specific embodiments, the particle size range of the lactose phthalocyanine / cytarabine nanomedicine with pH responsiveness is precisely controlled between 100 and 200 nanometers. This size range is intended to optimize the distribution, stability and targeting efficiency of the nanomedicine in the body. Specifically, when the particle size of the nanomedicine is within this range, they can effectively avoid rapid clearance by the kidneys, thereby prolonging the circulation time in the body. At the same time, nanoparticles of this size can more effectively pass through the gaps between vascular endothelial cells, enter tumor tissue or other target areas, and achieve more precise targeted delivery.

[0037] In addition, the pH-responsive properties of lactose phthalocyanine / cytarabine nanomedicines also make it possible to be used in complex biological environments. Under normal physiological pH conditions, nanomedicines may remain relatively stable, reducing the risk of premature drug release; when reaching tumor tissue or other acidic microenvironments, the decrease in pH triggers structural changes in nanomedicines, leading to effective drug release. This intelligent release mechanism not only improves the utilization rate of drugs, but also reduces toxic side effects on normal tissues.

[0038] In summary, lactose phthalocyanine / cytarabine nanodrugs have shown great application potential and advantages in the field of drug delivery due to their suitable particle size range and unique pH response characteristics.

[0039] A method for preparing the pH-responsive lactose phthalocyanine / cytarabine nanomedicine is as follows: lactose phthalocyanine and cytarabine are slowly added dropwise into water and allowed to stand for 1.5-2.5 hours to obtain a co-assembled nanomedicine.

[0040] In certain specific embodiments, the method for preparing lactose phthalocyanine involves the following steps: first, dichlorosilicon phthalocyanine, p-hydroxyphenylethylamine and sodium hydride (NaH) are mixed together, and the reaction temperature is controlled between 100-120° C. in an anhydrous toluene solvent environment and under a nitrogen protective atmosphere, and the substitution reaction is continued for up to 22-26 hours. After the reaction is completed, hydrochloric acid is added to the reaction mixture, and after the color of the water layer is observed to change to blue, an appropriate amount of sodium hydroxide aqueous solution is continued to be added until solid matter begins to precipitate, thereby obtaining diethylaminophenoxysilicon phthalocyanine.

[0041] Next, the obtained diethylaminophenoxysilicon phthalocyanine, lactobionic acid, 1-hydroxybenzotriazole and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride are mixed together and further substituted in a solvent environment of N,N-dimethylformamide (DMF). After the reaction is completed, the main blue component is carefully collected through multiple separation, purification and elution steps, and the final product is the desired lactobacillus phthalocyanine.

[0042] An application of the above-mentioned pH-responsive lactose phthalocyanine / cytarabine nanomedicine in the preparation of an integrated cancer diagnosis and treatment drug.

[0043] An application of the pH-responsive lactose phthalocyanine / cytarabine nanomedicine in fluorescence imaging.

[0044] An application of the pH-responsive lactose phthalocyanine / cytarabine nanodrug in photoacoustic imaging.

[0045] Example 1 Preparation of NanoPC

[0046] (1) Dichlorosilicon phthalocyanine (200 mg, 0.33 mmol), p-hydroxyphenylethylamine (224 mg, 1.64 mmol) and NaH (5 mg, 0.20 mmol) were reacted in 50 mL of anhydrous toluene at 110° C. under nitrogen protection for 24 hours. The product was washed with 50 mL of hydrochloric acid solution (pH=3.0). After the water layer turned blue, an appropriate amount of sodium hydroxide aqueous solution was added until solid precipitated, which was diethylaminophenoxysilicon phthalocyanine.

[0047] (2) Diethylaminophenoxysilicon phthalocyanine (40.50 mg, 0.05 mmol), lactobionic acid (105.77 mg, 0.30 mmol), 1-hydroxybenzotriazole (40.00 mg, 0.30 mmol), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (57.36 mg, 0.30 mmol) were reacted in DMF and then separated, purified, and eluted several times to collect the main blue component, which was axial lactobionic phthalocyanine PcL.

[0048] (3) Slowly drop lactose phthalocyanine and cytarabine into water in a proportion (molar ratio of 1:1) and let stand for 2 hours to obtain a co-assembled nanodrug.

[0049] Example 2

[0050] Aqueous solution (10 μM) of NanoPC (prepared in Example 1) was prepared, and its particle size was measured on a dynamic light scattering DLS (HORIBASZ-100) instrument, and its morphological characteristic image was observed using a transmission electron microscope (FEI G2 Spirit Biotwin). Photoacoustic intensity (PA) imaging was performed using a photoacoustic imaging system. Its ultraviolet-visible absorption spectrum was measured using a Shimadzu UV-2600 spectrophotometer, and the NanoPC fluorescence spectrum was obtained using an Agilent Cary Eclipse fluorescence spectrometer.

[0051] like Figure 1 As shown, (A) particle size distribution (DLS) of cytarabine (CYT), lactose phthalocyanine (PCL), and NanoPC (all 1 μM) dispersed in water; (B) display of NanoPC aqueous solution and its transmission electron microscope image; (C) change of photoacoustic intensity (PA) of cytarabine, lactose phthalocyanine, and NanoPC aqueous solution (all 1 μM) at different wavelengths; (D) ultraviolet absorption spectrum of cytarabine, lactose phthalocyanine, and NanoPC aqueous solution (all 1 μM); (E) fluorescence emission spectrum of cytarabine, lactose phthalocyanine, and NanoPC aqueous solution (all 1 μM), with an excitation wavelength of 610 nm.

[0052] Depend on Figure 1 It can be seen that the NanoPC prepared in the present invention is spherical, with an average particle size of about 140nm, mainly distributed in the range of 100-200nm ( Figure 1 A), the photoacoustic effect of NanoPC formed after co-assembly is enhanced ( Figure 1 C), the excitation wavelength is 700nm ( Figure 1 D), the fluorescence of NanoPC is lower than that of lactose phthalocyanine PcL ( Figure 1 E).

[0053] Example 3 Study on drug release and fluorescence intensity changes of NanoPC under different pH environments

[0054] The fluorescence spectra of NanoPC (1 μM) in PBS buffer solutions with pH values ​​of 7.4, 6.5, and 5.0 were obtained using a Gilent Cary Eclipse fluorescence spectrometer. Figure 2B), and the absorbance of free drug of NanoPC (1 μM) in PBS buffer solutions with pH values ​​of 7.4, 6.5 and 5.0 within 24 h was measured by UV spectrophotometer, and the percentage of free drug in total drug was calculated, and the drug release efficiency was calculated ( Figure 2 C), the morphological characteristics of NanoPC (1 μM) in PBS buffer solutions with pH values ​​of 6.5 and 5.0 were observed using transmission electron microscopy ( Figure 2 D).

[0055] Depend on Figure 2 It can be seen that NanoPC dissociates under weakly acidic conditions, releasing PcL to produce a fluorescent signal, and as the pH decreases, the fluorescence intensity emission becomes stronger; under pH 7.4 conditions, the fluorescence intensity of NanoPC does not change significantly, and it has good integrity in phosphate buffer solution; under pH 5.0 conditions, NanoPC continuously releases PcL within 24 hours, producing a strong fluorescence signal; under pH 5.0 conditions, the release rate in 24 hours reaches 65%, indicating that slightly acidic conditions can effectively drive NanoPC to release PcL; transmission electron microscopy images clearly show the decomposition of NanoPC under acidic conditions, and the degree of decomposition increases with the increase of hydrogen ion concentration.

[0056] Example 4 Photoacoustic and fluorescence imaging studies of NanoPC in cells

[0057] Intracellular fluorescence intensity: HepG2 human liver cancer cells and LO2 human normal liver cells (1×10 5 Each well (cells / well) was inoculated in a culture plate and cultured in the dark for 24 hours. After removing the original culture medium, the cells were incubated with NanoPC (10 μM) in the dark for 6 hours and then washed three times with PBS. Confocal laser scanning microscopy (CLSM) was used to obtain intracellular fluorescence images and measure the average intracellular fluorescence intensity. The sample was excited by light of 635 nm wavelength and the fluorescence imaging of phthalocyanine was captured at 645-750 nm. The average intracellular fluorescence intensity (60 cells per sample) was calculated as follows: Figure 3 As shown in A. Figure 3 A shows that the relative fluorescence intensity of HepG2 liver cancer cells after taking up PcL is 14.24, and the relative fluorescence intensity of HepG2 liver cancer cells after taking up NanoPC is 33.14, and the fluorescence intensity is increased by 2.32 times.

[0058] HepG2 cells were incubated with PcL and NanoPC (both at 10 μM) for 6, 12, 18, and 24 h, respectively, and the intracellular fluorescence intensity was detected by flow cytometry. Figure 3 As shown in C and D. Figure 3As shown in C and D, the fluorescence intensity of NanoPC is low in normal tissue, indicating that NanoPC is less distributed in normal tissue, and the fluorescence intensity is high in the tumor site, indicating that NanoPC is more distributed in normal tissue, indicating that it can perform selective targeted imaging of tumors.

[0059] Intracellular PA imaging: HepG2 human liver cancer cells (1×10 5 The cells were inoculated into a culture dish (10 μM / well) for 24 h, and then incubated with PcL, MB, and NanoPC (all at 10 μM) for 6 h. The culture medium was removed and the cells were washed with PBS three times. Subsequently, the cells were centrifuged (800 rpm / min), the supernatant was removed, and the cells were collected in a centrifuge tube. PA imaging was performed using a photoacoustic imaging system (720 nm). Figure 3 As shown in B. Figure 3 B shows that the relative photoacoustic intensity of HepG2 liver cancer cells after taking up PcL is 0.38, and the relative photoacoustic intensity of HepG2 liver cancer cells after taking up NanoPC is 1.72, and the photoacoustic intensity is increased by 4.53 times.

[0060] Example 5 Study on the generation of ROS, cell death and cytotoxicity of NanoPC under US irradiation

[0061] Detection of HepG2 cell viability by CCK8 assay

[0062] HepG2 cells were inoculated in a culture plate and cultured in the dark for 24 h. Then, HepG2 cells were incubated with 0, 0.02, 0.05, 0.1, 0.2, and 0.5 μM NanoPC and PcL for 6 h and washed three times with PBS. 2 ,1MHz,5min) irradiated the cells treated with sonosensitizer, and the dark control group was not irradiated. Finally, CCK-8 solution was added, and the absorbance of CCK-8 solution at 450nm was measured by microplate reader to calculate the cell viability. Figure 4 As shown in A. Figure 4 As shown in A, the results of the cell counting kit-8 also showed the dose-dependent cytotoxicity of ultrasound sensitizers. The 50% inhibition concentration (IC 50 ) value was 0.10±0.03μM.

[0063] The DCFH-DA probe was used to monitor the production of ROS in HepG2 cells induced by sonosensitizer.

[0064] HepG2 cells were incubated with PcL, NanoPC and PBS (all 10 μM) for 6 h. Then, the DCFH-DA probe was added and cultured for 1 h. The HepG2 cells were washed with PBS three times. Then, the sonodynamic therapy group was irradiated with ultrasound (1 W / cm 2 ,1MHz,5min), the control group was not given ultrasound irradiation. The fluorescence intensity of DCFH-DA was monitored by CLSM fluorescence imaging to further evaluate the generation of intracellular ROS. The probe was excited by light at a wavelength of 488nm, and fluorescence imaging was monitored at 530nm. Scale bar: 200μm. Figure 4 As shown in B, HepG2 cells without sonodynamic therapy do not produce ROS, while HepG2 cells co-cultured with PcL and NanoPC produce more ROS after sonodynamic therapy, with more green fluorescence. Among them, the ROS produced by HepG2 cells co-cultured with NanoPC is greater than that of HepG2 cells co-cultured with PcL and NanoPC. This shows that NanoPC has a good sonodynamic therapy effect.

[0065] HepG2 cells (1×10 5 / well) were inoculated in a culture plate and cultured in the dark for 24 hours, then incubated with PBS, PcL and NanoPC (all 10μM) for 6 hours, and the relevant groups were irradiated with ultrasound US (1W / cm2, 1MHz, 5min), while the control group was not irradiated. Subsequently, the cells were incubated with calcein-AM / PI dye for 30 minutes, washed three times with PBS, and the fluorescence images were detected by CLSM to show the dual staining of living cells and dead cells. The excitation and emission wavelengths of calcein produced by the hydrolysis of calcein-am are 490nm and 515nm, respectively, while the excitation and emission wavelengths of PI are 535nm and 617nm, respectively. Figure 4 C. Among them, (i) PBS, (ii) PcL+US, (iii) NanoPC, (iv) NanoPC, scale bar: 200μm. Figure 4 C shows that both NanoPC and PcL can effectively induce cells to emit DCF fluorescence under ultrasound irradiation, but NanoPC is more efficient. Compared with PcL, NanoPC can kill cells more effectively under ultrasound irradiation.

[0066] These results suggest that SDT and chemotherapy play an important role in the antitumor activity of NanoPC inducing HepG2 liver cancer cell death.

[0067] Example 6 Imaging and treatment of HepG2 liver cancer cell-bearing mouse model using NanoPC

[0068] Specific steps: NanoPC (100 μM, 150 μL) was injected into the tumor-bearing mice through the tail vein of the mice, and the fluorescence distribution in the body at different time points within 48 hours was monitored using a small animal fluorescence imager and a photoacoustic spectrometer, and the corresponding fluorescence intensity values ​​were recorded. In the evaluation of the anti-tumor activity of sonodynamic therapy and chemotherapy, NanoPC (100 μM, 150 μL) was also injected into the tail vein of tumor-bearing mice. After a period of injection, the tumor site of the mouse was irradiated with ultrasound US (1 MHz, 1.61 W·cm -2 ) for 8 minutes. To monitor the therapeutic effect, the width and length of the tumor were measured using a vernier caliper every two days and the tumor inhibition rate was calculated.

[0069] like Figure 5 Shown are (in vivo imaging of HepG2 liver cancer-bearing mice at different time points after tail vein injection of NanoPC (A), photoacoustic imaging (B), and weight changes of mice at different time points after receiving different treatments (C). H&E and TUNEL staining images of tumor tissues after treatment (D). Scale bar: 100 μm. Radiation (1 MHz, 1 W / cm 2 )). In Figure A, the fluorescence intensity was 1.03 24 hours after the injection of NanoPC, and 0.42 24 hours after the injection of PcL. The fluorescence intensity of the liver cancer site increased by 2.45 times after co-assembly; in Figure B, the fluorescence intensity was 1.01 24 hours after the injection of NanoPC, and 0.34 24 hours after the injection of PcL. The fluorescence intensity of the liver cancer site increased by 2.97 times after co-assembly. After intravenous injection of NanoPC into HepG2 liver cancer cell-bearing mice, NanoPC exhibited excellent fluorescence and photoacoustic dual-modality imaging performance in vivo. The fluorescence of the tumor site 24 hours after administration ( Figure 5 A) and photoacoustic signal ( Figure 5 B) reached the strongest, which can realize the detection and diagnosis of tumors under dual-modality imaging. At the same time, different treatment methods were used for tumor-bearing mice after administration (same dosage), among which the combination of sonodynamic therapy and chemotherapy had a better anti-tumor effect. Tumor growth was completely inhibited within 16 days after treatment, and the tumor weight was the lowest ( Figure 5 C), the tumor rate of H&E and TUNEL staining images of tumor tissue is also the lowest ( Figure 5 D), the tumor inhibition rate of NanoPC sonodynamic therapy was 91.6%.

[0070] In summary, the present invention proposes to use lactose phthalocyanine and cytarabine to co-assemble to form nanomedicines. The prepared co-assembled nanomedicines have a spherical structure with uniform particle size, which can effectively achieve drug enrichment at the tumor site and reduce toxic and side effects in other normal tissues. The lactose phthalocyanine contained in the co-assembled nanomedicine has excellent fluorescence imaging and photoacoustic imaging performance, and can achieve in vivo fluorescence and photoacoustic dual-modality imaging. In addition, the high acoustic sensitivity of lactose phthalocyanine and the chemotherapeutic effect of chemotherapeutic drugs can realize the combined application of sonodynamic therapy and chemotherapy in cancers such as liver cancer. At the same time, as the environmental pH decreases, the peripheral amino group of cytarabine is protonated, and the dissociation rate of the nanomedicine co-assembled by lactose phthalocyanine and cytarabine increases, and the drug release rate increases. The optical signal is enhanced, which increases the difference in the fluorescence imaging effect of normal tissues and tumor tissues. In view of the selective enrichment and low toxic and side effects of the co-assembled nanomedicine, and the integrated functions of diagnosis and treatment, the co-assembled nanomedicine in the present invention can provide a research basis for the clinical design and development of new integrated diagnosis and treatment drugs.

[0071] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A pH-responsive lactose phthalocyanine / cytarabine nanodrug, It is characterized in that It is a nano drug co-assembled from lactose phthalocyanine and cytarabine.

2. The pH-responsive lactose phthalocyanine / cytarabine nanodrug according to claim 1, It is characterized in that The molar ratio of lactose phthalocyanine to cytarabine is 1:4-4:

1.

3. The pH-responsive lactose phthalocyanine / cytarabine nanodrug according to claim 1, It is characterized in that The modification group of the lactose phthalocyanine is one of amino, vitamin and sugar.

4. The pH-responsive lactose phthalocyanine / cytarabine nanodrug according to claim 1, It is characterized in that Its particle size is 100-200nm.

5. A method for preparing the pH-responsive lactose phthalocyanine / cytarabine nanomedicine according to any one of claims 1 to 4, It is characterized in that Slowly add lactose phthalocyanine and cytarabine into water and let stand for 1.5-2.5 hours to obtain a co-assembled nano drug.

6. The method according to claim 5, It is characterized in that The preparation method of the lactose phthalocyanine comprises the following steps: (1) dichlorosilane phthalocyanine, p-hydroxyphenylethylamine and NaH are reacted in anhydrous toluene at 100-120° C. for 22-26 hours under nitrogen protection, hydrochloric acid is added, and after the water layer turns blue, an appropriate amount of sodium hydroxide aqueous solution is added until solids precipitate to obtain diethylaminophenoxysilane phthalocyanine; (2) Diethylaminophenoxysilicon phthalocyanine, lactobionic acid, 1-hydroxybenzotriazole, and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride are reacted in DMF, and then separated, purified, and eluted multiple times to collect the main blue group, which is lactobionic phthalocyanine.

7. Use of the pH-responsive lactose phthalocyanine / cytarabine nanomedicine according to any one of claims 1 to 4 in the preparation of an integrated cancer diagnosis and treatment drug.

8. Use of the pH-responsive lactose phthalocyanine / cytarabine nanomedicine according to any one of claims 1 to 4 in fluorescence imaging.

9. Use of the pH-responsive lactose phthalocyanine / cytarabine nanomedicine according to any one of claims 1 to 4 in photoacoustic imaging.